Safety and Efficacy of Salvecin (AR-301), a Human Monoclonal Antibody, in Patients with Severe Pneumonia Caused by S. aureus, a Phase 2 Study
Publications
Investor Presentation
Analysts Fireside Chat 2020
Fireside Chat Vimeo link
Aridis COVID-19 slides Cantor Fireside Chat
Cantor Fireside Video chat link
Aridis COVID-19 slides Maxim Conference
APEXTM Technology Presentation
Safety and tolerability of a single administration of AR 301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first in human trial
Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia
Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia
Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes
Pharmacokinetics and Safety Profile of the Human Anti-Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers